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The chart audit provided evidence that in the clinical practice
setting, detemir and glargine are equipotent and deliver similar
outcomes.
PDB62
IMPACT OF INSURANCE PAYMENT SYSTEMS ON QUALITY
OF CARE AND HEALTH CARE SERVICE UTILIZATION INTYPE
2 DIABETES MEDICAID ENROLLEES
Pawaskar MD1, Burch SP2, Nahata MC1, Seiber E3, Balkrishnan R3
1The Ohio State University College of Pharmacy, Columbus, OH,
USA, 2GlaxoSmithKline, Research Triangle Park, NC, USA, 3The Ohio
State University, Columbus, OH, USA
OBJECTIVES: The type of insurance payment system could
affect the quality of care, patient health outcomes and use of
health care resources in patients with chronic disease. The objec-
tive of this study was to examine the impact of the type of
insurance payment plan (Capitated vs. Fee-For-Service (FFS)) on
the quality of care, and health care service utilizations in type 2
diabetes Medicaid enrollees. METHODS: A retrospective data-
base analysis comprised of an equal mix of both capitated and
FFS type 2 diabetic patients (n = 8581) enrolled in the Medstat
MarketScan® MultiState Medicaid database from July 1, 2002
to December 31, 2005. Patients were followed for 6 months
before and 12 months after the index anti-diabetic medication to
collect the data on the baseline characteristics and study out-
comes. Logistic regressions were employed to measure the
quality of care (HbA1c tests, LDL-C tests, eye examinations) and
health care services utilization. RESULTS: A total of 3763 (44%)
of the patients was enrolled in capitated plans and 4818 (56%) in
FFS plans. Patients with capitated health plans had 44% more
likelihood of receiving at least 2 HbA1c tests (OR: 1.44; 95% CI:
1.29, 1.59) and 76% more likelihood of performing LDL-C tests
(OR: 1.76; 95% CI: 1.59, 1.93) compared to those with FFS
plans. The type of health plan did not have any signiﬁcant impact
on the likelihood of eye examination. Patients with capitated
health plans had 33% more likelihood of getting hospitalized
(OR: 1.33; 95% CI: 1.17, 1.49) while 16% more likelihood ER
visits (OR: 1.16; 95% CI: 1.06, 1.28) but 27% less number of
outpatient visits (b (SE) = -0.24 (0.02), p < 0.001) as compared
to those with FFS. CONCLUSIONS: Capitated plans were asso-
ciated with better quality of care (measured using HEDIS indi-
cators) however; it was not translated into reduced health care
utilization.
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OBJECTIVES: This study aimed to examine type 2 diabetic
patients’ resource use and costs associated with changes in dosing
regimen (monotherapy (MONO), dual therapy (DUAL), and
ﬁxed-dose combination therapy (FDCT)). METHODS: This
study utilized a retrospective cohort of Medicaid enrollees
from eight states with type 2 diabetes newly starting antidiabetic
therapy. Patients were followed for 12 months after initiation of
index dosing regimen (MONO, DUAL, or FDCT) and 12
months after early change in dosing regimen (DUAL or FDCT).
Demographic characteristics, pharmacy records, economic and
utilization-related variables were extracted for eligible patients.
Multiple log-linear regression analysis was employed to model
health care costs while multiple logistic regression analysis was
utilized to study likelihoods of change in therapy, hospitaliza-
tions, and ER visits. Zero-inﬂated negative binomial and negative
binomial regressions were employed to model counts of hospi-
talization and ER visits respectively. RESULTS: There were
10,749 patients in the study cohort including 8,528 (79.4%)
MONO, 1558 (14.5%) DUAL, and 663 (6.2%) FDCT patients.
No signiﬁcant different in distribution of age was found across
the three groups. Among the 1318 patients who changed their
therapy, 809 (61.4%) had an augmentation to DUAL and 509
(38.6%) switched to FDCT. Patients with higher MPR had lower
odd of switching to FDCT (p < 0.001). FDCT patients had 9.2%
lower costs than the augmentation to DUAL patients (p < 0.05).
Patients who switched to FDCT had 16.5% lower ER visits than
those patients who shifted to DUAL (p < 0.01). Age, race, gender,
comorbidities, and diabetes-related complications were also sig-
niﬁcant predictors of the outcomes. Medication adherence was
mainly associated with hospitalization and ER visit. CONCLU-
SIONS: By considering clinical proﬁle and therapy-related issues
of the patients, disease management programs can target patients
at-risk for poor outcomes and help them gradually reduce the
gap between actual adherence and optimal outcomes.
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OBJECTIVES: This study aimed to assess patients’ medication
adherence associated with changes in dosing regimen (mono-
therapy (MONO), dual therapy (DUAL), and ﬁxed-dose combi-
nation therapy (FDCT)) in type 2 diabetics. METHODS: This
study utilized a retrospective cohort of Medicaid enrollees
from eight states with type 2 diabetes newly starting antidiabetic
therapy. Patients were followed for 12 months after initiation of
index dosing regimen (MONO, DUAL, or FDCT) and 12
months after early change in dosing regimen (DUAL or FDCT).
Demographic characteristics and pharmacy records were
extracted for eligible patients. Prescription reﬁll patterns were
used to calculate Medication Possession Ratio (MPR). To
compare changes in adherence before and after a change in the
dosing regimen, Pre- and Post-index MPR were calculated. Dif-
ferences in MPR and demographics between groups were ana-
lyzed using T-tests and ANOVA for continuous variables and
chi-squared tests for categorical variables. RESULTS: There were
10,749 patients in the study cohort including 8,528 (79.4%)
MONO, 1,558 (14.5%) DUAL, and 663 (6.2%) FDCT patients.
No signiﬁcant different in distribution of age was found across
the three groups. Among the 1318 patients who changed their
therapy, 809 (61.4%) had an augmentation to DUAL and 509
(38.6%) switched to FDCT. Mean MPR for the entire cohort was
0.81. ANOVA indicated that medication adherence rates were
signiﬁcantly different across MONO, DUAL, and FDCT dosing
regimens (p < 0.001). Patients on dual therapy had signiﬁcantly
higher MPR rate (0.91) as compared to patients on the other
regimens. Patients switching to FDCT had signiﬁcantly lower
pre-index MPR than patients augmenting to dual therapy
(p-value < 0.01). Patients switching to FDCT also had signiﬁ-
cantly lower post-index MPR than the augmentation patients
(p-value < 0.001). CONCLUSIONS: Patients, health care pro-
viders like physicians, pharmacists, and Medicaid programs can
collaborate together to devise strategies to improve patient medi-
cation adherence and other outcomes.
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